To analyze the impact of the identified PVs on the clinical and pathological characteristics of early onset BC patients, we divided the cohort into BRCA1/2 carriers, non-BRCA1/2 carriers, and non-carriers (of PVs) (Table 1). Here, BRCA1 is linked to breast cancer.